by | Jul 21, 2022 | Uncategorized
A quadruplet regimen comprising the monoclonal antibody elotuzumab plus weekly carfilzomib, lenalidomide and dexamethasone conferred a 72% 3-year PFS rate among patients with newly diagnosed multiple myeloma, phase 2 trial results showed.Data from the study published...
by | Jul 18, 2022 | Uncategorized
Caregivers of patients with multiple myeloma reported significant psychological distress across the cancer care continuum compared with patients themselves, according to study results published in Blood Advances.“This study was prompted by my experience providing care...
by | Jul 18, 2022 | Uncategorized
Caregivers of patients with multiple myeloma reported significant psychological distress across the cancer care continuum compared with patients themselves, according to study results published in Blood Advances.“This study was prompted by my experience providing care...
by | Jul 13, 2022 | Uncategorized
Patients with multiple myeloma tumors that featured a three-gene signature demonstrated a higher likelihood of achieving a durable and deep response to selinexor, according to study results published in JCO Precision Oncology.Selinexor (Xpovio; Karyopharm...
by | Jul 6, 2022 | Uncategorized
Source: Cure Today articles The myeloma treatment group of the COVALENT-101 clinical trial recently started, analyzing the new drug BMF-219 in patients with relapsed or refractory disease. Read More
by | Jul 5, 2022 | Uncategorized
An investigational chimeric antigen receptor T-cell therapy provided via multiple infusions induced a 100% overall response rate among adults with relapsed or refractory multiple myeloma, results from a pilot study showed.More than half of patients who received the...
